Study Title: Lecanemab for Early Alzheimer's
Study Status: Ongoing
What's it about? This study is testing a new drug called lecanemab to see if it can slow down the progression of Alzheimer's disease.
Why did I choose it? I chose this study because it's one of the most promising new Alzheimer's treatments in development. The early results look really good, and if lecanemab is eventually approved, it could be a major breakthrough for people with Alzheimer's.
Who can participate? The study is open to people who are 55 years old or older and have been diagnosed with early Alzheimer's.
What happens if I participate? If you participate, you'll be randomly assigned to receive either lecanemab or a placebo. The study will last for 3 years, and the main goal is to see how the drug affects your cognitive function over time.
Where can I learn more? If you're interested in learning more about this study or participating in it, you can visit the ClinicalTrials.gov website.